There are 3397 resources available
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13
1139P - Final results of a phase II study of pembrolizumab as first-line treatment in advanced cutaneous squamous cell carcinomas (CSCCs)
Presenter: Eve Maubec
Session: Poster session 13
1140P - Cemiplimab versus historical systemic treatments for locally advanced (la) or metastatic (m) cutaneous squamous cell carcinomas (CSCC): Results from the French study TOSCA
Presenter: Emilie Gerard
Session: Poster session 13
1141P - Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma
Presenter: Elena Croce
Session: Poster session 13
1142P - Personalized decision making in cutaneous squamous cell carcinoma: Integrating a clinico-pathological model for absolute metastatic risk into the staging systems
Presenter: Marlies Wakkee
Session: Poster session 13
1143P - Changes in peripheral and local tumor immunity after cemiplimab treatment early describe clinical outcomes in patients with cutaneous squamous cell carcinoma
Presenter: Daniela Esposito
Session: Poster session 13